Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.

Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase Inhibitors: Similarities and Differences

Lennernäs, Hans, Fager, Gunnar·1997·Clinical Pharmacokinetics

Abstract

Hypercholesterolaemia plays a crucial role in the development of atherosclerotic diseases in general and coronary heart disease in particular. The risk of progression of the atherosclerotic process to coronary heart disease increases progressively with increasing levels of total serum cholesterol or low density lipoprotein (LDL) cholesterol at both the individual and the population level. The statins are reversible inhibitors of the microsomal enzyme HMG-CoA reductase, which converts HMG-CoA to mevalonate. This is an early rate-limiting step in cholesterol biosynthesis. Inhibition of HMG-CoA reductase by statins decreases intracellular cholesterol biosynthesis, which then leads to transcriptionally upregulated production of microsomal HMG-CoA reductase and cell surface LDL receptors. Subsequently, additional cholesterol is provided to the cell by de novo synthesis and by receptor-mediated uptake of LDL-cholesterol from the blood. This resets intracellular cholesterol homeostasis in extrahepatic tissues, but has little effect on the overall cholesterol balance. There are no simple methods to investigate the concentration-dependent inhibition of HMG-CoA reductase in human pharmacodynamic studies. The main clinical variable is plasma LDL-cholesterol, which takes 4 to 6 weeks to show a reduction after the start of statin treatment. Consequently, a dose-effect rather than a concentration-effect relationship is more appropriate to use in describing the pharmacodynamics. Fluvastatin…

Overview

Integrity signals

Registry

Crossref · 10.2165/00003088-199732050-00005

Cites

107 of 107 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 107 references

Cited by

See all 528

Metadata

Authors
Lennernäs, H., & Fager, G.
Affiliations
  • Uppsala University (SE)
  • University of Gothenburg (SE)
Corresponding author
Lennernäs, Hans
Venue
Clinical Pharmacokinetics
Published
1997-05
Volume
32
Issue
5
Pages
403-425
ISSN
0312-5963 (ISSN-L)
OpenAlex
W2032890774
Cited by
527
References
107
Citations by year
2026: 8 · 2025: 4 · 2024: 10 · 2023: 18 · 2022: 13 · 2021: 9 · 2020: 11 · 2019: 19 · 2018: 20 · 2017: 18 · 2016: 17 · 2015: 16 · 2014: 22 · 2013: 17 · 2012: 20
FWCI
19.54
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Pharmacokinetics (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords
statins, pharmacodynamics, pharmacokinetics, LDL cholesterol lowering, hypercholesterolemia, cholesterol biosynthesis, LDL receptor upregulation, dose-response relationship, fluvastatin, lovastatin, pravastatin, simvastatin, statin adverse effects, atherosclerosis, coronary artery disease
MeSH terms
Fluvastatin, Anticholesteremic Agents, Arteriosclerosis, Brain, Enzyme Inhibitors, Fatty Acids, Monounsaturated, Humans, Hypercholesterolemia, Indoles, Liver, Lovastatin, Pravastatin, Food-Drug Interactions, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase Inhibitors: Similarities and Differences. https://app.cochat.ai/papers/10.2165/00003088-199732050-00005
The paper
Lennernäs, H., & Fager, G. (1997). Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase Inhibitors: Similarities and Differences. Clinical Pharmacokinetics. https://doi.org/10.2165/00003088-199732050-00005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.